Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations
Conditions: Metastatic Colorectal Adenocarcinoma; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Pancreatic Adenocarcinoma; Stage IV Colorectal Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8 Interventions: Drug: Bendamustine; Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Computed Tomography; Drug: Cyclophosphamide; Procedure: Echocardiography; Drug: Fludarabine; Procedure: Leukapheresis; Procedure: Magnetic Resonance Imaging; Procedure: M ultigated Acquisition Scan; Procedure: Positron Emission Tomography; Biological: T-cell Receptor-engineered T-cells Sponsors: Fred Hutchinson Cancer Center; Affini-T Therapeutics, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Carcinoma | Colorectal Cancer | Mergers and Aquisitions | Non-Small Cell Lung Cancer | Pancreas | Pancreatic Cancer | PET Scan | Research | Treanda